<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630109</url>
  </required_header>
  <id_info>
    <org_study_id>GRMC120006</org_study_id>
    <nct_id>NCT01630109</nct_id>
  </id_info>
  <brief_title>Study of Metoclopramide in Small Bowel Capsule Endoscopy</brief_title>
  <official_title>Metoclopramide As An Adjunct To Small Bowel Capsule Endoscopy: Rate of Complete Evaluation And Affect on Transit Times</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genesys Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genesys Regional Medical Center</source>
  <brief_summary>
    <textblock>
      Patients undergoing small bowel capsule endoscopy will be randomized into 3 study groups to
      either receive 5 mg of metoclopramide, 10 mg of metoclopramide, or a placebo 30 minutes prior
      to swallowing the Pill Cam. This is a randomized, double-blind, placebo-controlled design.
      The outcomes to be assessed are capsule study completion rates, gastric transit time, small
      bowel transit time, and the effect of diabetes on pill capsule completion rates. The purpose
      of the study is to assess if metoclopramide given prior to pill capsule endoscopy has any
      effect on pill capsule completion rate, gastric transit time, small bowel transit time, and
      pill capsule completion rates in diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pill Capsule Endoscopy allows Gastroenterologists to visualize the mucosa of the small bowel
      beyond the reach of any endoscope and to an extent never before possible. It involves the
      ingestion of a small pill camera approximately the size of a large vitamin. 8 hours of images
      are transmitted to a sensor worn around the patient's waist. At the conclusion of the test,
      these images are downloaded to a computer for physician review. Meanwhile, the PillCam™
      passes naturally through the digestive system and does not require retrieval.

      Many of these pill capsule studies are incomplete due to failure of the pill capsule to reach
      the colon. Metoclopramide (brand name Reglan) is an anti-emetic that also has known
      pro-motility effects in the GI tract. The thought behind this study is that metoclopramide
      will increase the rate of passage of the pill capsule through the GI tract allowing a higher
      completion rate of the pill capsule studies.

      Patients scheduled for pill capsule endoscopy will be approached on the morning of their
      procedure to inform them of the research study. After proper consent is obtained the patient
      will receive either 5 mg Metoclopramide, 10 mg Metoclopramide, or a placebo pill 30 minutes
      prior to their pill capsule study. The pill capsule camera records 8 hours worth of data. The
      patient will return at the conclusion of their study to turn in their recorder. The ordering
      gastroenterologist will then read the study. Information regarding pill capsule completion
      (pill capsule goes through the ileocecal valve), gastric transit time, and small bowel
      transit time will then be recorded and analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Treatment vs. Placebo in Pill Capsule Completion Rates</measure>
    <time_frame>12 hours</time_frame>
    <description>This study is investigating whether there is a difference in pill capsule completion rates between a treatment group (metoclopramide) vs. placebo. It is also looking at differences in completion rates between two different doses of metoclopramide (5 mg vs. 10 mg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in Gastric Transit Time in Treatment vs. Placebo in Pill Capsule Studies</measure>
    <time_frame>12 hours</time_frame>
    <description>This study will investigate whether treatment with metoclopramide (5 mg or 10 mg) vs. placebo will affect gastric transit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Small Bowel Transit Time in Treatment vs. Placebo in Pill Capsule Studies</measure>
    <time_frame>12 hours</time_frame>
    <description>This study will investigate whether there is a difference in small bowel transit time in pill capsule studies with treatment with metoclopramide (5 mg or 10 mg) vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Pill Capsule Completion Rates in Diabetics vs. Non-diabetics</measure>
    <time_frame>12 hours</time_frame>
    <description>This study will investigate whether there is any difference in pill capsule completion rates in patients who are diabetic vs. those who are not diabetic.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Pill Capsule Endoscopy Completion Rates</condition>
  <arm_group>
    <arm_group_label>Metoclopramide 5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pro-motility agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopramide 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pro-motility agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to be used as the control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.</description>
    <arm_group_label>Metoclopramide 5 mg</arm_group_label>
    <arm_group_label>Metoclopramide 10 mg</arm_group_label>
    <other_name>Brand name of Metoclopramide is Reglan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo capsule made to look like the metoclopramide capsule.</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women over the age of 18 undergoing pill capsule endoscopy to investigate
             unexplained rectal bleeding, anemia, iron deficiency, abdominal pain, altered bowel
             habits, and/or weight loss.

        Exclusion Criteria:

          -  Inability to sign consent for research participation

          -  Inability to swallow PillCam™, placebo, or metoclopramide capsule

          -  Known hypersensitivity/allergy to metoclopramide

          -  Active congestive heart failure or respiratory failure requiring ventilator assistance

          -  Presence of cardiac pacemaker or implanted electromedical device

          -  Known bowel obstruction/stricture/fistula or intrauterine pregnancy

          -  Known history of Whipple procedure (pancreaticoduodenectomy), Billroth II surgery
             (partial gastrectomy with gastrojejunostomy), or gastric bypass surgery due to risk of
             capsule retention in a blind intestinal limb necessitating surgical retrieval

          -  Known history of seizure disorder, renal failure requiring dialysis, or
             pheochromocytoma

          -  Lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven D Brooks, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Genesys Regional Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genesys Regional Medical Center</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <results_first_submitted>August 23, 2013</results_first_submitted>
  <results_first_submitted_qc>January 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2014</results_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Genesys Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Steven Brooks</investigator_full_name>
    <investigator_title>DO/Internal Medicine Resident</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study subjects were recruited from December 2012 to June 2013. The subjects were recruited in the Medical Procedures Unit at Genesys Regional Medical Center.</recruitment_details>
      <pre_assignment_details>No events to report.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metoclopramide 5 mg</title>
          <description>Pro-motility agent</description>
        </group>
        <group group_id="P2">
          <title>Metoclopramide 10 mg</title>
          <description>Pro-motility agent</description>
        </group>
        <group group_id="P3">
          <title>Placebo Control</title>
          <description>Placebo to be used as the control group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metoclopramide 5 mg</title>
          <description>Pro-motility agent</description>
        </group>
        <group group_id="B2">
          <title>Metoclopramide 10 mg</title>
          <description>Pro-motility agent</description>
        </group>
        <group group_id="B3">
          <title>Placebo Control</title>
          <description>Placebo to be used as the control group</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="0"/>
                    <measurement group_id="B2" value="59" spread="0"/>
                    <measurement group_id="B3" value="46" spread="12.76"/>
                    <measurement group_id="B4" value="50.20" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Treatment vs. Placebo in Pill Capsule Completion Rates</title>
        <description>This study is investigating whether there is a difference in pill capsule completion rates between a treatment group (metoclopramide) vs. placebo. It is also looking at differences in completion rates between two different doses of metoclopramide (5 mg vs. 10 mg).</description>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide 5 mg</title>
            <description>Pro-motility agent</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide 10 mg</title>
            <description>Pro-motility agent</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Placebo to be used as the control group</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Treatment vs. Placebo in Pill Capsule Completion Rates</title>
          <description>This study is investigating whether there is a difference in pill capsule completion rates between a treatment group (metoclopramide) vs. placebo. It is also looking at differences in completion rates between two different doses of metoclopramide (5 mg vs. 10 mg).</description>
          <units>percentage of complete capsule studies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Gastric Transit Time in Treatment vs. Placebo in Pill Capsule Studies</title>
        <description>This study will investigate whether treatment with metoclopramide (5 mg or 10 mg) vs. placebo will affect gastric transit time.</description>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide 5 mg</title>
            <description>Pro-motility agent</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide 10 mg</title>
            <description>Pro-motility agent</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Placebo to be used as the control group</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Gastric Transit Time in Treatment vs. Placebo in Pill Capsule Studies</title>
          <description>This study will investigate whether treatment with metoclopramide (5 mg or 10 mg) vs. placebo will affect gastric transit time.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="0"/>
                    <measurement group_id="O2" value="57" spread="0"/>
                    <measurement group_id="O3" value="88" spread="106.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Small Bowel Transit Time in Treatment vs. Placebo in Pill Capsule Studies</title>
        <description>This study will investigate whether there is a difference in small bowel transit time in pill capsule studies with treatment with metoclopramide (5 mg or 10 mg) vs. placebo.</description>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide 5 mg</title>
            <description>Pro-motility agent</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide 10 mg</title>
            <description>Pro-motility agent</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Placebo to be used as the control group</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Small Bowel Transit Time in Treatment vs. Placebo in Pill Capsule Studies</title>
          <description>This study will investigate whether there is a difference in small bowel transit time in pill capsule studies with treatment with metoclopramide (5 mg or 10 mg) vs. placebo.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" spread="0"/>
                    <measurement group_id="O2" value="218" spread="0"/>
                    <measurement group_id="O3" value="301" spread="114.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Pill Capsule Completion Rates in Diabetics vs. Non-diabetics</title>
        <description>This study will investigate whether there is any difference in pill capsule completion rates in patients who are diabetic vs. those who are not diabetic.</description>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide 5 mg (Diabetics)</title>
            <description>Pro-motility agent given to diabetic patients</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide 10 mg (Diabetics)</title>
            <description>Pro-motility agent given to diabetic patients</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control (Diabetics)</title>
            <description>Placebo to be used as the control group in diabetic patients</description>
          </group>
          <group group_id="O4">
            <title>Metoclopramide 5 mg (Non-diabetic)</title>
            <description>Pro-motility agent given to non-diabetic patients</description>
          </group>
          <group group_id="O5">
            <title>Metoclopramide 10 mg (Non-diabetic)</title>
            <description>Pro-motility agent given to non-diabetic patients</description>
          </group>
          <group group_id="O6">
            <title>Placebo (Non-diabetic)</title>
            <description>Placebo control given to non-diabetics</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Pill Capsule Completion Rates in Diabetics vs. Non-diabetics</title>
          <description>This study will investigate whether there is any difference in pill capsule completion rates in patients who are diabetic vs. those who are not diabetic.</description>
          <units>Percentage of complete studies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metoclopramide 5 mg</title>
          <description>Pro-motility agent</description>
        </group>
        <group group_id="E2">
          <title>Metoclopramide 10 mg</title>
          <description>Pro-motility agent</description>
        </group>
        <group group_id="E3">
          <title>Placebo Control</title>
          <description>Placebo to be used as the control group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The main limitation of this study was that there was a lower number of capsule studies performed at the study center than anticipated so it was difficult to find patients to enroll.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Steven Brooks</name_or_title>
      <organization>Genesys Regional Medical Center Office of Research</organization>
      <phone>8106067722</phone>
      <email>Steven.Brooks@genesys.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

